Finanzen von Oric Pharmaceuticals Inc (ORIC)ORICOric Pharmaceuticals Inc

Evaluating the bottom line, ORIC Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.80%, provide a clear picture of how effectively ORIC converts its operational activities into shareholder value.

In the context of the broader market, ORIC competes directly with industry leaders such as CGEM and HROW. With a market capitalization of $1.44B, it holds a significant position in the sector. When comparing efficiency, ORIC's gross margin of N/A stands against CGEM's N/A and HROW's 71.27%. Such benchmarking helps identify whether ORIC Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

Oric Pharmaceuticals has reported consistent net losses, with a Q2 2026 net loss of $41.49 million and an EPS of -0.38, indicating ongoing challenges in achieving profitability.